Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells

Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib

(2018) Biagio Ricciuti et al.   MEDICAL ONCOLOGY

Good clinical response to alectinib, a second generation ALK inhibitor, in refractory neuroblastoma

(2018) John A. Heath et al.   PEDIATRIC BLOOD & CANCER

ALKALs are in vivo ligands for ALK family receptor tyrosine kinases in the neural crest and derived cells

(2018) Andrey Fadeev et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Alectinib versus crizotinib in treatment-naïve anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study

(2018) S Gadgeel et al.   ANNALS OF ONCOLOGY

Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children’s Oncology Group Study

(2017) Yael P. Mossé et al.   JOURNAL OF CLINICAL ONCOLOGY

Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

(2017) Toyoaki Hida et al.   LANCET

Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

(2017) Solange Peters et al.   NEW ENGLAND JOURNAL OF MEDICINE

Alk and Ltk ligands are essential for iridophore development in zebrafish mediated by the receptor tyrosine kinase Ltk

(2017) Elizabeth S. Mo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting ALK: Precision Medicine Takes on Drug Resistance

(2017) Jessica J. Lin et al.   Cancer Discovery

The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN

(2016) J. Guan et al.   Disease Models & Mechanisms

Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice

(2016) Joachim T. Siaw et al.   Oncotarget

Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations

(2015) Thomas F Eleveld et al.   NATURE GENETICS

Augmentor α and β (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: Hierarchy and specificity of ligand–receptor interactions

(2015) Andrey V. Reshetnyak et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Dynamics-Driven Allostery in Protein Kinases

(2015) Alexandr P. Kornev et al.   TRENDS IN BIOCHEMICAL SCIENCES

FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase

(2015) Jikui Guan et al.   eLife

Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance

(2014) Tatsushi Kodama et al.   CANCER LETTERS

Intragenic anaplastic lymphoma kinase (ALK) rearrangements: Translocations as a novel mechanism ofALKactivation in neuroblastoma tumors

(2014) Susanne Fransson et al.   GENES CHROMOSOMES & CANCER

Emergence of New ALK Mutations at Relapse of Neuroblastoma

(2014) Gudrun Schleiermacher et al.   JOURNAL OF CLINICAL ONCOLOGY

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

(2014) Benjamin J. Solomon et al.   NEW ENGLAND JOURNAL OF MEDICINE

The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma

(2014) G. Umapathy et al.   Science Signaling

Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer

(2013) Justin F. Gainor et al.   JOURNAL OF CLINICAL ONCOLOGY

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study

(2013) Takashi Seto et al.   LANCET ONCOLOGY

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study

(2013) Yael P Mossé et al.   LANCET ONCOLOGY

The genetic landscape of high-risk neuroblastoma

(2013) Trevor J Pugh et al.   NATURE GENETICS

Characterization of Rearrangements Involving the ALK Gene Reveals a Novel Truncated Form Associated with Tumor Aggressiveness in Neuroblastoma

(2012) A. Cazes et al.   CANCER RESEARCH

Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma

(2012) D. Chand et al.   Disease Models & Mechanisms

NIH Image to ImageJ: 25 years of image analysis

(2012) Caroline A Schneider et al.   NATURE METHODS

Aberrant activation of ALK kinase by a novel truncated form ALK protein in neuroblastoma

(2012) J Okubo et al.   ONCOGENE

Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells

(2012) C Schönherr et al.   ONCOGENE

Children's Oncology Group's 2013 blueprint for research: Neuroblastoma

(2012) Julie R. Park et al.   PEDIATRIC BLOOD & CANCER

Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684

(2011) Christina Schönherr et al.   BIOCHEMICAL JOURNAL

Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802)

(2011) Kazutomo Kinoshita et al.   BIOORGANIC & MEDICINAL CHEMISTRY

CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant

(2011) Hiroshi Sakamoto et al.   CANCER CELL

Appearance of the Novel Activating F1174S ALK Mutation in Neuroblastoma Correlates with Aggressive Tumor Progression and Unresponsiveness to Therapy

(2010) T. Martinsson et al.   CANCER RESEARCH

Recent Advances in Neuroblastoma

(2010) John M. Maris   NEW ENGLAND JOURNAL OF MEDICINE

EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors

(2010) Young Lim Choi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

Protein kinases: evolution of dynamic regulatory proteins

(2010) Susan S. Taylor et al.   TRENDS IN BIOCHEMICAL SCIENCES

Defining the conserved internal architecture of a protein kinase

(2009) Alexandr P. Kornev et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

High incidence of DNA mutations and gene amplifications of theALKgene in advanced sporadic neuroblastoma tumours

(2008) Helena Carén et al.   BIOCHEMICAL JOURNAL

Identification of ALK as a major familial neuroblastoma predisposition gene

(2008) Yaël P. Mossé et al.   NATURE

Activating mutations in ALK provide a therapeutic target in neuroblastoma

(2008) Rani E. George et al.   NATURE

Oncogenic mutations of ALK kinase in neuroblastoma

(2008) Yuyan Chen et al.   NATURE

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma

(2008) Isabelle Janoueix-Lerosey et al.   NATURE